AML Clinical Trials in Nashville, Tennessee

4 studies are recruiting for aml in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

    This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.

    Stage
    Phase 1
    Ages
    18 to 85
    Site
    Sarah Cannon Research Insitute, Nashville, Tennessee
    Locations
    5 in total
    Run by
    CERo Therapeutics Holdings, Inc.

    See if you can join NCT06834282 on ClinicalTrials.gov

  2. Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Vanderbilt University Medical Center, Nashville, Tennessee
    Locations
    45 in total
    Run by
    Kura Oncology, Inc.

    See if you can join NCT06001788 on ClinicalTrials.gov

  3. A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

    This is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in participants with …

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute - TriStar Bone Marrow Transplant (BMT), Nashville, Tennessee
    Locations
    26 in total
    Run by
    TScan Therapeutics, Inc.

    See if you can join NCT07702578 on ClinicalTrials.gov

  4. A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

    This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with A…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    SCRI - TriStar Bone Marrow Transplant, Nashville, Tennessee
    Locations
    21 in total
    Run by
    TScan Therapeutics, Inc.

    See if you can join NCT05473910 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.